LJPC - La Jolla Pharmaceutical Company

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

La Jolla Pharmaceutical Company

4550 Towne Centre Court
San Diego, CA 92121
United States
858-207-4264
http://lajollapharmaceutical.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees169

Key Executives

NameTitlePayExercisedYear Born
Dr. George F. TidmarshPres, CEO, Sec. & Director675.97kN/A1960
Ms. Jennifer A. CarverChief Operating Officer529.12kN/A1954
Dr. Lakhmir S. ChawlaChief Medical Officer529.43kN/A1971
Mr. Dennis M. MulroyChief Financial OfficerN/AN/A1955
Mr. James M. RolkeChief Scientific OfficerN/AN/A1969
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California.

Corporate Governance

La Jolla Pharmaceutical Company’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.